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Abstract: Three international nosologies have been proposed for the diagnosis of Marfan 
syndrome (MFS): the Berlin nosology in 1988; the Ghent nosology in 1996 (Ghent-1); and the 
revised Ghent nosology in 2010 (Ghent-2). We reviewed the literature and discussed the chal-
lenges and concepts of diagnosing MFS in adults. Ghent-1 proposed more stringent clinical 
criteria, which led to the confirmation of MFS in only 32%–53% of patients formerly diagnosed 
with MFS according to the Berlin nosology. Conversely, both the Ghent-1 and Ghent-2 nosolo-
gies diagnosed MFS, and both yielded similar frequencies of MFS in persons with a causative 
FBN1 mutation (90% for Ghent-1 versus 92% for Ghent-2) and in persons not having a causative 
FBN1 mutation (15% versus 13%). Quality criteria for diagnostic methods include objectivity, 
reliability, and validity. However, the nosology-based diagnosis of MFS lacks a diagnostic refer-
ence standard and, hence, quality criteria such as sensitivity, specificity, or accuracy cannot be 
assessed. Medical utility of diagnosis implies congruency with the historical criteria of MFS, 
as well as with information about the etiology, pathogenesis, diagnostic triggers, prognostic 
triggers, and potential complications of MFS. In addition, social and psychological utilities of 
diagnostic criteria include acceptance by patients, patient organizations, clinicians and scientists, 
practicability, costs, and the reduction of anxiety. Since the utility of a diagnosis or exclusion 
of MFS is context-dependent, prioritization of utilities is a strategic decision in the process of 
nosology development. Screening tests for MFS should be used to identify persons with MFS. 
To confirm the diagnosis of MFS, Ghent-1 and Ghent-2 perform similarly, but Ghent-2 is easier 
to use. To maximize the utility of the diagnostic criteria of MFS, a fair and transparent process 
of nosology development is essential.
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Introduction
Marfan syndrome (MFS) is a disorder of the connective tissue that is inherited in 
an autosomal dominant fashion and is caused by mutations in the gene coding for 
fibrillin-1 (FBN1). MFS has a low prevalence with similar frequency in both sexes and 
in all countries and races. MFS is a severe, chronic, and life-threatening disease with 
multiorgan involvement without availability of a curative therapy.1 MFS is associated 
with chronic fatigue and pain, as well as with psychological despair that compromises 
the quality of life and imposes restrictions on the autonomy of affected persons.2–7
A classical study of life expectancy from the era prior to the availability of therapy 
documented poor survival of persons with MFS in the early 1970s.1 The study docu-
mented 74 deaths in 257 affected persons with 50% of men and women dead at the 
age of 40 years and 48 years, respectively, which corresponded to a reduction of life 
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expectancy by 30%–40% when compared to the normal 
population. The mean age of death was 32 years, whereby 
fatalities resulted from rupture of aortic aneurysm in 12 
(16%) patients, dissection of aortic aneurysm in eight (11%), 
surgical death at attempted repair of the aorta in four (5%), 
insufficiency of the aortic valve in 14 (19%), congestive 
heart failure in eight (11%), bacterial endocarditis in two 
(3%), ventricular fibrillation after orthopedic surgery in one 
(1%), sudden unexplained death in three (5%), and suicide 
in one (1%) person, whereas the remaining patients died of 
miscellaneous reasons or of unknown causes.1
The evolution of aortic surgery offered life-saving 
therapy for patients with acute aortic rupture and dissec-
tion, as well as prophylactic treatment to prevent patients 
with aortic root aneurysm from developing aortic rupture 
or dissection.8 The various modifications of the technique of 
Bentall and De Bono, with complete replacement of the aor-
tic root, became the operation of choice starting in the early 
1970s.9–11 In addition, a classical open-label randomized trial 
of propranolol in adolescents and adults with MFS showed 
that prophylactic beta-adrenergic blockade (BAB) was 
effective in slowing the rate of aortic dilatation and reduc-
ing the development of aortic complications in some MFS 
patients.12 Subsequently, a retrospective multicenter study 
documented that the life expectancy of patients with MFS 
had increased by over 25% since 1972, where benefits were 
documented from both cardiovascular surgery and medical 
therapy including BAB.13 Since this study, the introduction 
of valve-sparing techniques for the replacement of the aortic 
root has resulted in a major improvement of life quality by 
obviating the risk for coagulation, where the technique of 
David yielded the best results.14–17 Alternatives for BAB 
have been tested in numerous, mostly small nonrandomized 
trials. These studies used angiotensin-converting enzyme 
inhibitors, calcium channel blockers, or angiotensin-receptor 
blockers.18–22 Results from these studies were conflicting. 
Very recently, a randomized double-blind trial in young 
patients with MFS showed equally beneficial effects with 
atenolol as compared to losartan, with no differences with 
regards to side effects, giving us the opportunity to choose 
either option.23–25
Once the diagnosis of MFS is suspected, care for patients 
should be coordinated in specialized centers. With the help 
of such centers, along with the support of regional Marfan 
patient organizations, affected persons can have a normal 
life expectancy with an acceptable quality of life.26,27 In this 
article, we review the literature and discuss the challenges 
and concepts of diagnosing MFS in adults.
Prevalence of MFS
A number of studies have assessed the prevalence of MFS. 
The earliest study comes from Northern Ireland and it reports 
1.5 affected persons per 100,000 of the population, with a 
gene frequency of 0.729 per 100,000.28 A second study that 
screened 29,067 children from 18 provinces and cities of 
the People’s Republic of China from 1951 to 1987 reported 
five children with MFS, giving a prevalence of 17.2 per 
100,000 of the population, with a gene frequency of 8.61 per 
100,000 inhabitants, and a penetrance of 71.69%.29 A study 
of the population of Tayside and northeast Scotland identi-
fied 30 patients with MFS alive on prevalence day June 30, 
1991, corresponding to an estimated prevalence of 1:14,691 
or 6.81 per 100,000 inhabitants.30 Based on 239 persons 
(122 males, 117 females) with MFS who were alive and living 
in  Denmark by January 1, 1993, a fourth nation-wide study 
from Denmark identified a prevalence of 4.6 persons with 
MFS per 100,000 of the Danish population with an estimated 
average birth rate of 0.96 per 10,000 live born.31 Our study of 
adults with MFS identified a prevalence of seven in 100,000 
adults in the Hamburg metropolitan area.32 Finally, a national 
cohort study from Taiwan identified 2.329 persons with MFS 
in a study period from 2000 to 2012 and calculated an aver-
age prevalence of 10.2 persons with MFS (95% confidence 
interval [CI]: 9.8–10.7) per 100,000 persons of the Taiwanese 
population, with a minimal birth rate incidence (estimated 
among those aged 20–29 years) of 23.3 per 100,000 (95% 
CI: 21.7–23.3) individuals.33 Table 1 provides an overview 
of the existing studies on the prevalence of MFS.
Taken together, all studies provide lower prevalence 
rates than do the widely cited estimate of one per 5,000 
 individuals.34 Interestingly, these studies document a wide 
range from 1.5–17.2 per 100,000, or 0.075–0.86 per 5,000 
individuals in the general population.28–33 However, all reported 
prevalence rates are far less than one in 2,000 citizens, and 
hence MFS complies with the European definition of a rare 
disease.35 The wide range of the reported prevalence in the 
different studies reflects the usage of different diagnostic cri-
teria of MFS, but it also seems likely that the medical workup 
in the different countries has led to the different estimates of 
population frequency. In fact, there is increasing evidence for 
the under-diagnosis of MFS in the general population, where 
the search for the “needle in the haystack” may pose a major 
diagnostic dilemma of MFS (Figure 1A).
For instance, there is a marked delay in the diagnosis 
of MFS. The European Organisation for Rare Diseases 
(EURORDIS) performed a survey of patients with rare 
diseases in 18 European countries, where 682 families affected 
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Table 1 Studies on the prevalence of MFS in the general population
Author Population Number of patients with MFS,  
size of population
Prevalence of MFS  
per total population
Lynas28 Population of Northern ireland MFS: 20 
Population: 1,370,921
1.5 per 100,000
Sun et al29 Children from 18 provinces and cities  
of the People’s Republic of China
Children with MFS: 5 
Children from population: 29,067
17.2 per 100,000
Gray et al30 Population of Scotland MFS: 30 
Population of Tayside and northeast Fife: 441,000
6.8 per 100,000
Fuchs31 Population of Denmark MFS: 239 
Population: 5,180,614
4.6 per 100,000
Rybczynski et al32 Adult population of the Hamburg,  
Germany, metropolitan area
Adults with MFS and MFS-like syndromes: 207 
Adult population: 3.5 million
7 per 100,000
Chiu et al33 Population of Taiwan Population: 22,765,535 
MFS: 2,329
10.2 per 100,000
Abbreviation: MFS, Marfan syndrome.
diagnosis of MFS, and they discuss factors such as asym-
metry of information among physicians, a behavioral pattern 
of “organized irresponsibility”, which might be facilitated 
through the availability of more physicians, a lack of long-
term and sustained physician–patient relationships, and the 
lack of networking between physicians.39,41–44
In summary, the identification of persons with MFS in the 
general population remains a diagnostic dilemma because it 
is not realistic to screen the entire population for a rare dis-
ease, and there is no simple way to define a target population. 
However, whenever a risk for MFS may be identified, targeted 
screening may be performed with tests like the “seven-signs” 
screening tool (Figures 1 and 2).45–48 In addition, young 
patients with aortic dissection, or family members of a person 
who died at a young age from aortic dissection, should also 
be considered for diagnostic testing for MFS.49
Manifestations of MFS
MFS is a multiorgan disease affecting the skeleton, the 
cardiovascular system, the eyes, the lungs, the skin, and the 
nervous system.50,51 Individuals who have MFS do not exhibit 
all manifestations of MFS, and nosologies for diagnosing 
MFS select those manifestations as diagnostic criteria that 
are considered relevant. In this review, we propose five types 
of diagnostic contents, which together define the relevance of 
each sign, manifestation, or criterion of MFS (Table 2). The 
first is history: changes of diagnostic criteria should avoid 
large shifts in the population of people already labeled as 
having or not having MFS. Accordingly, the criteria of MFS 
should be largely congruent with the picture of MFS that 
evolved throughout the history of the syndrome. The second 
type of information is etiology and pathogenesis: demonstra-
tion of a causative FBN1 mutation or of pathogenetic changes 
by MFS were included.36 The time between the first clinical 
manifestations and diagnosis was 2 years for half of the patients 
with MFS, but it was as long as 4.5 years for 25% of patients. 
During the quest for diagnosis, more than five physicians were 
consulted by 38% of families and more than 20 physicians 
by 7% of families. Prior to obtaining the correct diagnosis of 
MFS, another diagnosis was given to 25% of patients, result-
ing in delayed diagnosis and inappropriate treatment in 81% 
of the patients. For 72% of families, the delay in diagnosis 
was considered responsible for deleterious consequences.36 
Similarly, a cohort study of all hospitalized patients with 
a diagnosis of MFS and related disorders in  England still 
documents a high rate of cardiovascular events.37 This study 
documents 159 patients with aortic dissection, 101 with stroke, 
and eleven with rupture of an abdominal aortic aneurysm in a 
total of 4,468 hospitalized MFS patients over a mean follow-up 
of 6.9 years.37 Moreover, current data from autopsy studies 
suggest that the rate of MFS patients who die from aortic dis-
section outside the hospital is still as high as 7.8%.38
Based on administrative data from 389 patients with MFS, 
Roll39 documented a negative linear relationship between the 
density of physicians in a given region and the probability of 
an immediate diagnosis of MFS, whereby a higher number 
of visits to physicians was associated with a significantly 
decreased probability of immediate diagnosis. Moreover, 
they found that the distance to medical health care centers 
was not a predictor of an immediate diagnosis.39 The authors 
argue that diagnostic errors rarely occur because of a lack of 
knowledge about a rare disease, but rather because of cogni-
tive errors in the process of gathering the right information 
about the patient, and in putting together heterogeneous 
information about the disease.40 More importantly, they see 
structural deficiencies as a major cause of the delay in the 
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Family history of Marfan syndrome
– 2 points –
Previous thoracic aortic
surgery – 1 point –
Wrist and thumb sign
– 1 point –
History of pneumothorax
– 1 point –
Ectopia letis
– 4 points –
Skin striae
– 1 point –
Pectus excavatum
 – 1 point –
Figure 2 “Seven-signs” of Marfan syndrome may be used for targeted screening of 
Marfan syndrome in adults of the general population.
Notes: The screening tool assigns four score points to ectopia lentis, two points 
to a family history of Marfan syndrome, and one point to previous thoracic aortic 
surgery, to pectus excavatum, to a wrist and thumb sign, to previous pneumothorax, 
and to skin striae. According to the total score, the pretest probability of Marfan 
syndrome may be assessed as low (#1 point), moderate (.1–3.5 points), or high 
(.3.5 points).48
Dilemma of diagnostics (“needle in a haystack”)A
B
C
Quality of diagnostics
Utility of diagnostics
(acceptance
through science,
economics, laws,
ethics)
(reduction of
uncertainties
and anxieties)
(guidance of
medical
decisions)
Validity
Research
(searches persons with no definitive diagnosis
for new syndromes)
Nosology
(confirms or excludes MFS in suspects)
Targeted screening
(“seven signs”, complications, and autopsy
search population for suspects)
The general population with MFS
(prevalence 1.459–7.2 per 100,000)
Population of suspects with MFS
(% of persons of general population with MFS
but no suspicion of MFS remains unknown)
Population with definitive diagnosis
(13%–81% with definitive MFS)
Objectivity
Reliability
Psychological Medical
Social
Figure 1 Dilemma, quality and utility of diagnosis of Marfan syndrome.
Notes: (A) The rarity of MFS poses a dilemma, where an unknown fraction of 
persons with MFS may not be suspected of having MFS, or he or she may only 
be identified by major complications or at necropsy. (B) Criteria to estimate the 
quality of diagnostic criteria, such as the Ghent nosologies, comprise objectivity, 
reliability, and validity, where objectivity is a prerequisite for reliability, and reliability 
a prerequisite for validity. when a diagnosis is reliable, then all three qualities 
should converge. (C) The utility of diagnostic criteria includes medical, social, and 
psychological dimensions, which depend on context and may diverge. To maximize 
the overlap of all three dimensions, negotiation, compromise, and consensus are 
useful for developing diagnostic criteria.
Abbreviation: MFS, Marfan syndrome.
that indicate progressive organ disease, such as increased 
transforming growth factor (TGF-β1) serum levels or aortic 
medial degeneration, can reduce diagnostic and prognostic 
uncertainty. Third, diagnostic triggers are manifestations that 
prompt suspicion of MFS in formerly undiagnosed subjects. 
Fourth, prognostic triggers are manifestations such as aortic 
dilatation or mitral valve prolapse that, fifth, may give rise 
to complications such as aortic dissection or mitral valve 
regurgitation (Table 2).
History
Table 3 provides a brief history of the initial descriptions of 
frequent or typical manifestations of MFS. This tabulation of 
their initial descriptions may be somewhat arbitrary, because 
the criteria used for defining both MFS and manifestations 
have varied since the initial description of the disease and, 
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Table 2 Diagnostic content of various signs, manifestations, or criteria of MFS
Type of 
information
Sign, manifestation, or criterion – or their combination – is frequent and typical of MFS
High Moderate Low
History MFS as a heritable triad of  
skeletal, ocular, and cardiovascular  
manifestations74
Dilatation and dissection of the  
descending aorta, MvP, PAD, Pneu,  
skin striae, De
Calcification of the mitral valve annulus
etiology and  
pathogenesis
Autosomal dominant inheritance, FBN1  
mutation as an exclusive cause of MFS55
Alteration of TGF-β1 signaling70–72,107 CMN108–110
Diagnostic  
triggers
wrist and thumb sign,45,46 eL, FH  
of MFS, previous thoracic aortic  
surgery, pectus excavatum, history  
of Pneu, skin striae48,111
Body height in males $1.90 m and  
in females $1.78 m; previous surgery  
of the lens or of the spinal column48
MVP, PAD, joint hypermobility,  
hernia,32,83 skeletal muscle myopathy,112  
De,89,113,114 liver cysts, renal cysts,  
cholelithiasis115
Prognostic  
triggers
AoDD5 Thoracic/abdominal aortic dilatation,116  
MvP,90,117 SDB,20,21 myocardial dysfunction  
including increased NT-proBNP levels,118–123  
eL, myopia, apical pulmonary blebs124,125
PAD126, skeletal malformations,127  
osteopenia,128 De89
Complications Dissection or rupture of the  
ascending aorta, AR
Thoracic/abdominal aortic dissection  
or rupture,129,130 MvR,91,131 ie, HF,132  
SCD,122,123,133 retinal detachment,  
glaucoma, amaurosis,51 Pneu134
Rupture or dissection of MPA,126,135  
restrictive ventilatory defect,136 impaired  
cardiorespiratory function,137 lumbar  
or sacral radiculopathy,138 atlantoaxial  
or lumbal subluxation,139,140 bone fractures,128 
intrapelvic meningocele,141 dural leak with 
postural headache,142 bronchiectasis,143 
recurrent or incisional hernia32,144
Abbreviations: MFS, Marfan syndrome; MvP, mitral valve prolapse; PAD, pulmonary artery dilatation; Pneu, pneumothorax; De, dural ectasia; TGF-β1, transforming growth 
factor-beta 1; CMN, cystic media necrosis; eL, ectopia lentis; FH, family history; AoDD, aortic diameter at the sinuses of valsalva dilatation; SDB, sleep-disordered breathing; 
NT-proBNP, N-terminal probrain natriuretic peptide; AR, aortic valve regurgitation; MvR, mitral valve regurgitation; ie, infective endocarditis; HF, heart failure; SCD, sudden 
cardiac death; MPA, main pulmonary artery.
accordingly, descriptions of the history of MFS keep varying 
between authors. Nonetheless, some important lessons on 
the diagnosis of MFS may be derived from the analysis of 
 history. First, initial descriptions of the syndrome relied on 
signs that can easily be observed, such as “spider-like” fingers 
and toes, chest wall deformities, and scoliosis. Accordingly, 
the syndrome was initially named after obvious presenting 
signs in the skeleton and musculature. Second, an essential 
step in the description of MFS was the description of major 
complications. Ironically, all early reports of such complica-
tions described atrial septal defects, patent ductus arteriosus, 
and aortic coarctation as congenital cardiovascular malforma-
tions of MFS, none of which are considered typical mani-
festations of MFS today. Third, ocular abnormalities, such 
as ectopic lenses, have been considered essential to the syn-
drome since their first description in 1912.52,53  Maumenee54 
even speculated that the ophthalmologist E Williams might 
have provided the first description of MFS with his report of 
familial occurrence of dislocated lenses as early as June 1875. 
Ectopia lentis might be a classical example for a diagnostic 
sign that is both specific for MFS and clinically relevant 
because it can restrict the quality of life and the autonomy 
of patients. Finally, the heredity of the syndrome was rec-
ognized relatively soon after its discovery, which underpins 
the importance of the nature of a disease that affects whole 
families rather than isolated individuals.
etiology and pathogenesis
Mutations in the FBN1 gene are today considered the exclu-
sive cause of MFS.55 Mutations in other genes were excluded 
as causes of MFS. Nonetheless, FBN1 mutation analysis has 
diagnostic limitations. First, a small portion of FBN1 muta-
tions remains undetected in persons with MFS, most likely 
because of technical limitations.56 Second, databases identify 
more than 1,500 different disease-causative FBN1 mutations, 
but there is no single FBN1 genotype feature that qualifies as 
a reliable  predictor of disease evolution.57,58 Third, in some rare 
circumstances, mutations can present with phenotypes that 
do not fulfill clinical criteria of MFS, such as children with a 
purely skeletal phenotype, Shprintzen–Goldberg syndrome, 
or  Weill–Marchesani syndrome.56,59–61 Finally, an increasing 
number of nucleotide variants of the FBN1 gene have uncertain 
clinical significance and these introduce new uncertainties.62,63
FBN1 mutations initiate pathogenetic cascades that result in 
various manifestations and complications of MFS. One patho-
genetic mechanism is structural weakness of the tissue, which 
presents as marked and premature degeneration of the medial 
layer of the aortic wall.64 However, these changes are not specific 
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Table 3 Historical perspective on advances in the diagnosis of MFS
Author Year of  
publication
Feature Comments
Initial description of the important features of MFS
Marfan145,146 1896 New syndrome,  
“dolichosténomelié”
Description of a 5-year-old girl with multiple joint contractures, thoracolumbar 
kyphoscoliosis, and long, thin limbs and fingers and toes, which he called “spider-like”. 
Marfan termed the syndrome “dolichosténomelié”. As Behan noted, Marfan considered 
muscle involvement to be integral, with the small muscles “recalling atrophy”.112
Achard147 1902 “Dolichosténomelié”  
renamed as  
“arachnodactyly”
Description of a patient with loose-jointedness of the hands, hypognathia, and 
dolichostenomelia. Achard described excessively slender and hypermobile fingers of 
normal length, which he called “arachnodactyly”.
Salle148 
Piper and  
irvine-Jones149 
Apert150 
McKusick151
1912 
1926 
 
1938 
1955
Syndrome with  
“congenital  
cardiovascular disease”
Salle described a 1.5-month-old patient with pulmonary systolic murmur, an enlarged 
heart, and persistent foramen ovale at autopsy. Piper and irvine-Jones described a  
1.75-year-old patient with arachnodactyly presenting with systolic thrill and patent  
foramen primum at autopsy. Apert described patent ductus arteriosus in a patient with 
MFS, and McKusick reported aortic coarctation in MFS.
Börger52 
von Pfaundler53
1914 
1914
ectopia lentis and  
high-grade myopia
Description of a 1-year-old female with dolichostenomelic habitus who exhibited luxation 
of the lenses, iridodonesis with enlarged cornea, and hydrophthalmos. According to  
Rados,74 Börger and von Pfaundler published the same patient. Börger reported a second 
patient, a 9-year-old boy with dolichostenomelic habitus who presented with severe  
iridodonesis and high-grade myopia (-16 diopters and -20 diopters).
weve152 1931 Autosomal  
dominant trait
weve described the heritable nature of the condition and the primary involvement  
of tissue derived from embryonic mesoderm. He also associated Marfan’s name with  
the phenotype for the first time, and suggested the term “Dystrophia mesodermalis  
congenital, Typus Marfan”.
Jéquier153 1943 Pneumothorax Description of a 38-year-old Marfan patient with spontaneous pneumothorax as a  
consequence of the rupture of a pulmonary cyst.
Baer et al154 1943 Aortic dilatation Description of a 14-year-old and a 26-year-old arachnodactylic adult  
with sudden death who both exhibited aneurysm of the aorta at autopsy.
etter and  
Glover155
1943 Aortic dissection Description of a 21-year old man with ectopia lentis and arachnodactyly presenting with  
systolic and diastolic aortic murmur showing dissecting aneurysm with rupture into the  
pericardial sac, as well as aortic valve insufficiency at autopsy.
Tung and  
Liebow156
1952 Dilatation of the  
pulmonary artery
Description of idiopathic congenital dilatation of the pulmonary artery in an infant 
with MFS.
McKusick151 1955 MFS as disorder of  
connective tissue
The initial description of MFS as a heritable disorder of connective tissue. This  
comprehensive description is today considered the first nosology of MFS.
Nelson157 1958 widening of the  
spinal canal
Description of widening of the spinal canal with posterior scalloping of the vertebral 
bodies in four patients with MFS.
Kachele158 1960 Striae distensae Description of striations in a Marfan patient as typical striae distensae elasticae.  
McKusick159 pointed out that the initial description of striae in MFS dates back to 1936.
Bowden  
et al160
1965 Mitral valve prolapse Description of the patulous nature of the mitral valve and elongated chordae as the  
likely mechanics of mitral regurgitation where the elongated chordae may allow for  
prolapse of the valve leaflets into the left atrium in a Marfan patient.
Beals and  
Hecht161,162
1971 Congenital contractural  
arachnodactyly syndrome
Beals and Hecht described the congenital contractural arachnodactyly syndrome  
and proposed that this was the condition affecting Marfan’s original patient.
Dietz et al55 1991 etiology of MFS Description of a mutation in the FBN1 gene as the cause of MFS.
History of targeted screening for MFS
Steinberg45 1966 Thumb sign Steinberg proposed the thumb sign as a simple, quick screening test to “truly 
distinguish lanky, thin persons who have spidery fingers, wear thick-lensed glasses,  
and who appear prematurely old” from those with MFS.
walker and  
Murdoch46
1970 wrist sign walker and Murdoch proposed the wrist sign as a complement to the thumb sign, 
which “when used together at the bedside provide useful confirmation of the skeletal 
disproportion which occurs in patients with the Marfan syndrome”.46
Mueller et al47 2013 The Kid-Short  
Marfan Score (Kid-SMS)
A simple clinical model to estimate the probability of MFS in children.
Sheikhzadeh  
et al48
2012 The “seven-signs”  
screening instrument for  
adults with MFS
A simple clinical model to estimate the probability of MFS in adults.
(Continued)
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Table 3 (Continued)
Author Year of  
publication
Feature Comments
Early systematic reviews and international nosologies of MFS
Rados74 1942 Review of Marfan  
patients published  
until 1940
extensive case by case review and tabulation of Marfan patients published until  
1940. The review includes a statistical survey of the literature, which includes  
204 patients (101 males, 103 females) with detailed clinical information including  
manifestations and outcomes.
McKusick163 1956 Review of MFS  
phenotype
First report that might be considered an early nosology of MFS.
Beighton  
et al164
1988 First international  
nosology
The so-called Berlin nosology was the first international nosology of heritable  
disorders of the connective tissues.
De Paepe  
et al76
1996 Second international  
nosology
The so-called Ghent nosology was the revision of the Berlin nosology of heritable  
disorders of connective tissue. This nosology was the first to consider genetic data as 
diagnostic criteria.
Loeys et al79 2010 Third international  
nosology
The so-called revised Ghent nosology was the revision of the initial Ghent nosology 
for MFS.
Abbreviation: MFS, Marfan syndrome.
to MFS and in clinical practice, they can only be diagnosed with 
invasive methods.65 Indirect measurements of arterial stiffness 
parameters like pulse wave velocity or augmentation index can 
predict progression of aortic disease in MFS, but again this is 
not specific for MFS.66–69 Another major pathogenetic mecha-
nism is the dysregulation of TGF-β1 that has a causal role in 
the evolution of various features of the Marfan. The causal role 
of TGF-β1 for the phenotypic features of MFS was identified in 
a mouse model, and humans with MFS exhibit increased serum 
levels of TGF-β1, which decrease with successful treatment 
of aortic disease with BAB, angiotensin-receptor blockers, 
or angiotensin-converting enzyme inhibitors.18,70–72 However, 
such increases of TGF-β1 levels are not specific for aortic 
disease, but rather relate to the cumulative severity of organ 
involvement in MFS.73 Moreover, increased TGF-β1 serum 
levels are not specific to MFS, but they also occur in bicuspid 
aortic valve disease or Loeys–Dietz syndrome.73 In summary, 
exclusive FBN1 mutations currently qualify as the sensitive and 
specific causative or pathogenetic criteria of MFS.
Diagnostic triggers
In a series of 329 adults, general practitioners gave the fol-
lowing signs and manifestations as reasons for referral for 
diagnostic clarification of suspected MFS: a family history of 
Marfan features in 24%, aortic aneurysm or dissection both in 
24%; skeletal features in 22%; MFS diagnosed in childhood 
in 10%; eye manifestations in 9%; miscellaneous reasons in 
4%; nonaortic cardiovascular findings in 3%; and a history 
of pneumothorax, tissue weakness, and hypermobility in 
2%. These reasons for referral reflect the perception of MFS 
as a familial disease of the aorta, which can be recognized 
through the presence of skeletal features and typical eye 
manifestations. Indeed, this perception is in accord with the 
time-honored historical descriptions of MFS. Interestingly, 
however, the percentage of confirmation of MFS was highest 
in persons who were referred for MFS already diagnosed in 
childhood (88%), for eye manifestations (83%), for a family 
history of Marfan features (52%), and for aortic aneurysm 
or dissection (50%). Conversely, the percentage of confir-
mation of MFS was low in persons who were referred for 
pneumothorax (43%), skeletal features (30%), tissue weak-
ness and hypermobility (14%), and nonaortic cardiovascular 
findings in none.48 In particular, tall stature, scoliosis, or 
joint hypermobility seem to be perceived as typical features 
of MFS. However, MFS was rarely confirmed in persons in 
whom MFS was suspected because of the presence of these 
signs.48
Table 3 highlights that very early in the history of MFS, 
clinicians felt the need to find methods that helped to rapidly 
and specifically identify persons with MFS in the general 
population. In 1966, Steinberg was the first to propose the 
thumb sign as a simple, quick screening test – as he put it – 
to truly distinguish lanky, thin persons who have spidery 
fingers, wear thick-lensed glasses, and appear prematurely 
old from those with MFS.45 Since then, three other tools for 
targeted screening have been proposed to rapidly identify 
suspects of MFS based on a simple history and clinical signs 
(Figure 2).45–48
Finally, Table 3 provides a brief history of early sys-
tematic reviews and nosologies of MFS that had a major 
impact on the diagnosis and recognition of the syndrome. 
It is remarkable that as early as 1942, Rados74 performed a 
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systematic review of 204 patients published in the literature 
(101 males, 103 females), in which he described MFS 
as a heritable disease with a triad of skeletal, ocular, and 
cardiovascular manifestations. Since then, it has not been 
possible to identify a single definitive criterion to prove 
or refute MFS. Rather, common efforts were necessary to 
define an international consensus on the rules of how to 
diagnose MFS.
Prognostic triggers and complications
The risk for aortic dissection and rupture increases with 
growth of the aortic diameter, and hence the dilatation of 
the aortic root is a highly important prognostic trigger in 
MFS.75 However, other manifestations of MFS can also 
trigger complications: dilatation of the thoracic or abdominal 
aorta and sleep-disordered breathing can lead to dissection 
or rupture; mitral valve prolapse to severe insufficiency 
or infective endocarditis; myocardial dysfunction to heart 
failure or sudden cardiac death; ectopia lentis or myopia 
to retinal detachment, glaucoma, or amaurosis; and apical 
pulmonary blebs to pneumothorax. Similarly, in some rare 
instances, dilatation of the main pulmonary artery can lead 
to dissection or rupture; skeletal malformations to impaired 
cardiorespiratory function, radiculopathy, or atlantoaxial or 
lumbal subluxation; osteopenia to fractures; and dural ectasia 
to intrapelvic meningocele and to dural leak with postural 
headache (Table 2).
The Ghent nosology (Ghent-1)
The first Ghent nosology was introduced in 1996 (Ghent-1), 
and it presented the revision of the criteria of the first inter-
national nosology, the so-called Berlin nosology (Table 4). In 
essence, Ghent-1 was the response to the new insights gained 
from the discovery of FBN1 gene mutations as the etiology 
of MFS.76 The authors of the Ghent-1 nosology specified as 
reasons for their new nosology that the Berlin nosology relied 
completely on clinical criteria, and that the MFS phenotype 
had to be better separated from normal variation and from 
mild connective tissue phenotypes, such as the MASS phe-
notype (myopia, mitral valve prolapse, borderline and non-
progressive aortic root dilatation, skeletal findings, and striae) 
and mitral valve prolapse syndrome (MVPS).76 Of greatest 
concern were the misdiagnoses of relatives that arose by rely-
ing solely on the Berlin nosology after unequivocal diagnosis 
in a first-degree relative. Molecular evidence had shown that 
the criterion of a positive family history could produce a bias 
in favor of overdiagnosis. Accordingly, the authors stated as 
the most notable revisions the formulation of more stringent 
requirements for the diagnosis of MFS in relatives of an 
unequivocally affected individual; greater diagnostic weight 
on skeletal involvement, which constituted a major criterion 
if at least four of eight typical skeletal manifestations were 
present; contribution of molecular analysis, which the authors 
wanted neither to ignore nor to overemphasize; and delinea-
tion of the initial criteria for the diagnosis of other heritable 
conditions with partially overlapping phenotypes. The authors 
identified the diagnostic relevance of molecular data, espe-
cially in situations where clinical information concerning a 
relevant first-degree relative was unavailable, and both clini-
cal and genotype data were available on a second-degree or 
more distant relative(s). On the other hand, they argued that 
since methods for the characterization of mutations in FBN1 
were not entirely sensitive, and that the possibility of locus 
heterogeneity could not be completely ruled out, the inability 
to define an FBN1 mutation or the stringent documentation 
of recombination between FBN1 and the MFS phenotype did 
not constitute exclusion criteria.
Table 4 provides the entire list of criteria of MFS accord-
ing to the Berlin and Ghent-1 nosologies. Ghent-1 mentions 
six organ systems with diagnostic relevance for MFS. For 
each of these organ systems, the nosology provides lists of 
manifestations that alone or in combination constitute major 
or minor criteria for MFS. In each organ system, the nosol-
ogy distinguished between fulfillment of a major criterion, 
fulfillment of a minor criterion, and involvement of an organ 
system, where the combination of manifestations from the list 
of major criteria and from the list of minor criteria, or only 
from one of both lists was required. In addition, in the list 
of minor criteria of the skeletal system, three of five facial 
signs had to be present to fulfill one item in the list of minor 
criteria. For a final diagnosis, Ghent-1 distinguished between 
two diagnostic scenarios. First, for the index case: if the 
family or genetic history was not contributory, major criteria 
in at least two different organ systems and involvement of 
a third organ system were required for the diagnosis. If an 
FBN1 mutation known to cause MFS in others was detected, 
one major criterion in one organ system and involvement of 
a second organ system were required. Second, for a relative 
of an index case: The presence of a major criterion in the 
family history and one major criterion in an organ system, as 
well as involvement of a second organ system were required 
(Table 4).76
Two studies compared the diagnostic performance of 
the Berlin and Ghent-1 nosology. The first study was only 
published as an abstract, and it found that 60 of 104 (58%) 
patients evaluated for suspected MFS were diagnosed as 
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Table 4 Comparison of the diagnostic criteria of MFS according to the Berlin versus Ghent-1 nosology
Berlin nosology Ghent-1 nosology
Skeletal manifestations Skeletal system – major criterion ($4 of the major criteria from  
the following list):
Anterior chest deformity, especially asymmetric pectus  
excavatum/carinatum
Pectus carinatum
Pectus excavatum that requires surgery
Dolichostenomelia not due to scoliosis or tall stature,  
especially when compared to unaffected first-degree  
relatives
Upper-to-lower-segment ratio ,0.85 or arm span-to-height ratio .1.05
Arachnodactyly Positive wrist and thumb sign
Medial displacement of the medial malleolus causing pes planus
vertebral column deformity: scoliosis; thoracic  
lordosis; or reduced thoracic kyphosis
Scoliosis .20° or spondylolisthesis
extension at elbows ,170°
Protrusio acetabulae Protrusio acetabuli of any degree
Skeletal system – minor criteria (skeletal involvement with two of the 
major criteria or one of the major and two of the minor criteria)
Pectus excavatum not requiring surgery
Abnormal appendicular joint mobility: congenital  
flexion contractures; hypermobility
Joint hypermobility
High, narrowly arched palate and dental crowding High-arched palate with crowding of teeth
Facial features (3/5): dolichocephaly; enophthalmos; downslanting palpebral fissures; 
malar hypoplasia; retrognathia
Ocular manifestations Ocular system – major criterion
ectopia lentis* ectopia lentis of any degree
Ocular system – minor criteria (ocular involvement with $2 minor criteria):
Flat cornea Flat cornea
elongated globe, retinal detachment, myopia increased axial length of the globe (.23.5 mm)
Hypoplastic ciliary muscle causing decreased miosis
Cardiovascular manifestations Cardiovascular system – major criteria
Dilatation of the ascending aorta* Aneurysm of the ascending aorta involving at least the sinuses of valsalva
Aortic dissection,* aortic regurgitation Dissection of the ascending aorta
Cardiovascular system – minor criteria (cardiovascular involvement with 
one major or $1 minor criterion)
Mitral regurgitation due to mitral valve prolapse,  
mitral valve prolapse
Mitral valve prolapse (irrespective of mitral regurgitation)
Dilatation of the main pulmonary artery ,40 years of age (unassociated with pulmonic 
stenosis)
Calcification of the mitral annulus Calcification of the mitral annulus ,40 years of age
Abdominal aortic aneurysm; dysrhythmia; endocarditis Dilatation or dissection of the descending thoracic or abdominal aorta ,50 years  
of age
Pulmonary manifestations Pulmonary system – minor criteria (pulmonary involvement with $1 minor 
criteria)
Spontaneous pneumothorax Spontaneous pneumothorax
Apical bleb Apical blebs (radiography)
Skin and integument Skin and integument – minor criteria (skin and integumental involvement 
with $1 minor criteria)
Striae distensae Striae distensae
inguinal hernia, other hernia (umbilical,  
diaphragmatic, incisional)
Recurrent or incisional hernia
Central nervous system manifestations Dura: major criterion
Dural ectasia,* lumbosacral meningocele, dilated  
cisterna magna, learning disability (verbal performance  
discrepancy), hyperactivity with or without attention  
deficit disorder
Lumbosacral dural ectasia
Genetics Family and genetic history (present with $1 major criterion)
First-degree relative who independently meets the Marfan criteria
Autosomal dominant inheritance Mutation in FBN1 known to cause MFS
25%–30% of cases are sporadic; paternal age effect Haplotype around the FBN1 locus inherited via descent and is unequivocally associated 
with a diagnosed Marfan in the family
(Continued)
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Table 4 (Continued)
Requirements for diagnosis Requirements for diagnosis
In the absence of an unequivocally affected first-degree  
relative: involvement of the skeleton and at least two  
other systems; at least one major manifestation. 
in the presence of at least one unequivocally  
affected first-degree relative: involvement of  
at least two systems; at least one major  
manifestation preferred, but this will depend  
somewhat on the family’s phenotype.
For the index case: if the family/genetic history is not contributory, then major criteria 
in at least two different organ systems and involvement of a third organ system. if a 
mutation known to cause MFS in others is detected, then one major criterion in an 
organ system and involvement of a second organ system. 
For a relative of an index case: the presence of a major criterion in the family history, 
as well as one major criterion in an organ system and involvement of a second organ 
system.
Notes: Berlin nosology: *major diagnostic manifestations. Data from Beighton et al.164 Ghent-1 nosology: distinction between a major criterion and the organ system “being 
involved”, which is less important than a major criterion. Data from De Paepe et al.76
Abbreviation: MFS, Marfan syndrome.
having MFS according to the Berlin nosology, of whom only 
33 (32%) patients were confirmed by Ghent-1.77 The second 
study found that 48 of 73 (66%) patients (aged 1 month to 
62 years) evaluated for suspected MFS were diagnosed as 
having MFS according to the Berlin nosology, of whom 
only 39 (53%) patients were confirmed by Ghent-1.78 Both 
studies, however, did not screen for FBN1 mutations in 
those 45% and 19% of patients who met the Berlin, but not 
the Ghent-1, criteria, respectively. The authors of the first 
study raised the concern that using the Ghent-1 criteria 
“in patient care [meant that] under-diagnosing is replacing 
over-diagnosing”.77 Conversely, the authors of the second 
study concluded that Ghent-1 appropriately excluded some 
patients, but that further long-term follow-up or reliable 
molecular diagnostic techniques were necessary to estab-
lish the relative sensitivity and specificity of the Berlin and 
Ghent criteria.78
In summary, Ghent-1 proposed more stringent clinical 
criteria that led to confirmation of MFS by Ghent-1 in only 
32% and 53% of patients in the two studies available who 
had previously been diagnosed of MFS according to the 
Berlin nosology.
The revised Ghent nosology 
(Ghent-2)
The revised version of the Ghent nosology was introduced in 
2010 (Ghent-2).79 The authors of the Ghent-2 nosology listed 
the following as aims of the revision: first, identification of 
patients with a risk for aortic aneurysm or dissection; second, 
simplicity of use of diagnostic criteria; third, allowance for 
early diagnosis; fourth, consideration of availability and 
costs of diagnostic tests; fifth, better definition of entities 
such as familial ectopia lentis, the MASS phenotype, and 
MVPS; and, finally, delineation of triggers for alternative 
diagnoses such as Loeys–Dietz syndrome.79 The authors 
listed five major changes, which comprised the following: 1) 
more diagnostic weight on aortic root aneurysm or dissection 
and ectopia lentis; 2) a more prominent role of molecular 
genetic testing; 3) complete removal of some clinical criteria, 
such as dilatation of the main pulmonary artery, dilatation 
or dissection of the descending thoracic or abdominal aorta, 
increased axial length of the globe and abnormally flat cor-
nea, hypoplastic iris or hypoplastic ciliary muscle causing 
decreased miosis, joint hypermobility, spondylolisthesis, 
highly arched palate, and recurrent or incisional herniae, 
calcification of the mitral annulus, apical blebs of the lung, 
or mitigation of the diagnostic relevance of dural ectasia, or 
adding or modifying clinical criteria such as myopia .-3 
diopters, hindfoot valgus, and thoracolumbar kyphosis; 
4), provision of discriminating features of alternative diag-
noses such as Loeys–Dietz syndrome; and 5) provision of 
context-specific recommendations for patient counseling 
and follow-up.79
Table 5 provides the entire list of criteria of MFS accord-
ing to Ghent-2. In brief, in the absence of a family history 
of MFS, MFS is diagnosed in the presence of aortic root 
dilatation combined with ectopia lentis, or a causative FBN1 
mutation, or a systemic score $7 points, or with the com-
bination of ectopia lentis with an FBN1 mutation known to 
cause aortic dilatation. In the presence of a family history, 
MFS is diagnosed with the demonstration of ectopia lentis, 
or a  systemic score $7 points, or aortic root dilatation 
(Z-scores $2 standard deviations [SD] above the mean with 
an age above 20 years, or Z-scores $3 SD above the mean 
with an age below 20 years).
Table 6 lists five studies that performed a direct comparison 
of the diagnostic performance of Ghent-1 and  Ghent-2.80–84 
Faivre et al80 concluded that if Ghent-2 criteria were applied 
with common sense and flexibility, they should help and support 
clinicians who are less experienced with the MFS phenotype. 
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Table 5 Diagnostic criteria of MFS according to the Ghent-2 nosology
In the absence of family history:
1. Aortic root diameter (Z-score $2) and ectopia lentis = MFS* 
2. Aortic root diameter (Z-score $2) and causal FBN1 mutation = MFS 
3. Aortic root diameter (Z-score $2) and systemic score $7 points = MFS* 
4. ectopia lentis and causal FBN1mutation with known aortic root dilatation = MFS
In the presence of family history:
5. Ectopia lentis and family history of MFS (as defined above) = MFS 
6. Systemic score $7 points and family history of MFS (as defined above) = MFS* 
7.  Aortic root diameter (Z-score $2 above 20 years old, $3 below 20 years) and family history of MFS (as defined above) = MFS*
*Caveat: without discriminating features of Shprintzen–Goldberg syndrome, Loeys–Dietz syndrome or vascular form of ehlers–Danlos syndrome 
AND after TGFBR1/2, collagen biochemistry, COL3A1 testing if indicated.
Scoring of systemic features of MFS
 1. wrist and thumb sign – 3 points (wrist or thumb sign – 1 point)
 2. Pectus carinatum deformity – 2 points (pectus excavatum or chest asymmetry – point)
 3. Hindfoot deformity – 2 points (plain pes planus – 1 point)
 4. Protrusio acetabuli – 2 points
 5. Reduced upper segment/lower body segment ratio and increased arm/height and no severe scoliosis – 1 point
 6. Scoliosis or thoracolumbar kyphosis – 1 point
 7. Reduced elbow extension – 1 point
 8. Facial features (3/5) – 1 point (dolichocephaly, enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia)
 9. Pneumothorax – 2 points
10. Skin striae – 1 point
11. Myopia .3 diopters – 1 point
12. Mitral valve prolapse (all types) – 1 point
13. Dural ectasia – 2 points
The systemic features number 1–13 are used for the systemic score in the Ghent-2 nosology, where a maximum total score points of 20 points can 
be obtained. we number the systemic features as 1–8 and address these as “skeletal score”, and the systemic features as 9–12 and address these as 
“non-skeletal score”.73
Note: Copyright © 2010. BMJ Publishing Group Ltd. Reproduced from Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. 
J Med Genet. 2010;47(7):476–485.79
Abbreviation: MFS, Marfan syndrome.
They recommended regular aortic follow-up in every patient 
with a diagnosis of ELS, MASS, or MVPS who does not reach 
the diagnosis of MFS. Radonic et al81 found that the calculation 
of Z-scores according to the Ghent-2 criteria underestimated 
aortic root dilatation, especially in patients with a large body 
surface area, a problem that was fixed by the subsequent publi-
cation of improved nomograms.85–87 Aalberts et al82 found that 
Ghent-2 led to a significant increase in the number of non-MFS 
diagnoses, which he found was due to lowering of the diag-
nostic threshold of MVPS. In addition, the authors concluded 
that Ghent-2 afforded a more straightforward diagnosis of 
MFS. Sheikhzadeh et al83 found that the Ghent-1 criteria were 
useful when no genotyping was available, but that when gene 
sequencing is available, Ghent-2 could be assessed more easily 
and more rapidly than Ghent-1. Finally, Yang et al84 reported that 
almost all the adult Korean patients who fulfilled the Ghent-1 
criteria also fulfilled the Ghent-2 criteria. 
Table 6 summarizes the Ghent-1 and Ghent-2 diagnoses 
of MFS in relation to the presence or absence of a causative 
FBN1 mutation. When not considering both early studies of the 
Ghent criteria, which exclusively included patients with FBN1 
mutations and MFS, or with the FBN1 mutation  MFS-like 
phenotype, our analysis documented that the Ghent-1 and 
Ghent-2 nosologies both yielded similar frequencies of MFS 
in persons with a causative FBN1 mutation (90% versus 92%) 
and in persons not having a causative FBN1 mutation (15% 
versus 13%).80,81 The study by Sheikhzadeh et al83 documented 
that 245 of 300 persons with suspected MFS had an identical 
likelihood of exclusion or confirmation of MFS with both 
nosologies (82%). Table 7 illustrates the diagnostic yield of 
Ghent-1 and Ghent-2 in studies of patients evaluated for sus-
pected MFS, where MFS was diagnosed in 34% versus 35%, 
other syndromes in 26% versus 28%, and where no definitive 
diagnosis could be established in 40% versus 38%. Interest-
ingly, only the proportion of diagnoses differed across the three 
studies, but not the results between Ghent-1 and Ghent-2. In 
summary, the review of the literature illustrates a similar diag-
nostic performance of Ghent-1 and Ghent-2 nosologies.
Prospects for reducing the 
inaccurate diagnoses of MFS
Classical criteria to estimate the quality of diagnosis com-
prise objectivity, reliability, and validity (Figure 1B). The 
diagnosis of MFS will be objective when diagnostic tests 
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Table 7 Diagnostic yield in suspected MFS according to Ghent-1 
versus Ghent-2
Study MFS Other  
syndromes
No definitive 
diagnosis
Aalberts et al82
Ghent-1 44/343 (13%) 96/343 (34%) 203/343 (59%)
Ghent-2 47/343 (14%) 118/343 (34%) 178/343 (52%)
Sheikhzadeh et al83
Ghent-1 126/300 (42%) 90/300 (30%) 84/300 (28%)
Ghent-2 128/300 (43%) 80/300 (27%) 92/300 (31%)
Yang et al84
Ghent-1 86/106 (81%) 6/106 (6%) 14/106 (14%)
Ghent-2 84/106 (79%) 8/106 (8%) 14/106 (15%)
All studies
Ghent-1 256/749 (34%) 192/749 (26%) 301/749 (40%)
Ghent-2 259/749 (35%) 206/749 (28%) 284/749 (38%)
Abbreviation: MFS, Marfan syndrome.
can be performed, analyzed, and interpreted in a standard-
ized fashion that is independent of the individual clinician 
performing the analysis. Ghent-2 formulates diagnostic rules 
that are simpler and require both less diagnostic testing and 
less clinical expertise than Ghent-1. Similarly, Ghent-2 dis-
cards some “subjective qualifiers” of diagnostic features, and 
it introduces criteria for causality of FBN1 mutations. These 
changes indeed are likely to enhance objectivity. In contrast, 
Ghent-2 does not specify which of the many criteria for mitral 
valve prolapse and dural ectasia should be used for diagnos-
ing MFS.88–91 This may have a negative impact on objectivity 
when assessing these signs, especially when clinicians use 
different criteria in the same patient. However, mitral valve 
prolapse and dural ectasia are features of the systemic score 
that only have a minor impact on the diagnosis of MFS.80 
Altogether, therefore, the objectivity of Ghent-2 is likely be 
higher than that of Ghent-1.
Clearly, objectivity is a prerequisite, but it may not neces-
sarily lead to improved reliability. Until today, there is no study 
that compares intrasubject, intraobserver, and interobserver 
variation in the application of the Ghent-1 and Ghent-2 criteria. 
However, the overall diagnostic yield of MFS and alternative 
diagnoses is similar with both nosologies, which may argue for 
similar reliability (Table 7). However, there is no evidence that 
Ghent-2 has actually improved diagnostic reliability.
Finally, the diagnosis of MFS will be valid when MFS 
is correctly identified or excluded. However, to estimate 
Table 6 Comparison of diagnosis of MFS according to Ghent-1 versus Ghent-2
Study FBN1  
mutation
Ghent-1 Ghent-2
MFS  
diagnosed
MFS not  
diagnosed
MFS  
diagnosed
MFS not 
diagnosed
Faivre et al80
Design and patients 1,009 patients with FBN1 mutation and phenotype compatible with type 1 fibrillinopathy, with reevaluated 
according to Ghent-2. A total of 54% were male, median age of 20 years (range: birth–72 years).
Presence of FBN1 mutation 1,009 894/1,009 (89%) 115/1,009 (11%) 842/1,009 (83%) 167/1,009 (17%)
Radonic et al81
Design and patients 180 adults with MFS according to Ghent-1 were reevaluated according to Ghent-2. A total of 53% were male, 
mean age of 37 years (range 18–62 years).
Presence of FBN1 mutation 180 164/180 (91%) 16/180 (9%)
Aalberts et al82
Design and patients 343 adults with suspected MFS. A total of 51% were male, mean age of 40±14 years.
Presence of FBN1 mutation 45 34/45 (76%) 11/45 (24%) 36/45 (80%) 9/45 (20%)
Absence of FBN1 mutation 95 10/95 (11%) 85/95 (89%) 9/95 (9%) 86/95 (91%)
Sheikhzadeh et al83
Design and patients 300 adults with suspected MFS. A total of 50% were male, mean age of 35±13 years (range 16–69 years).
Presence of FBN1 mutation 140 126/140 (90%) 14/140 (10%) 128*/140 (89%) 12/140 (9%)
Absence of FBN1 mutation 160 21/160 (13%) 139/160 (87%) 19/160 (12%) 141/160 (88%)
Yang at al84
Design and patients 106 adults with suspected MFS, all with genetic analysis of FBN1. A total of 57% were male, mediian age of 36 
years (range 20–69 years).
Presence of FBN1 mutation 74 74/74 (100%) 0 74/74 (100%) 0
Absence of FBN1 mutation 32 12/32 (38%) 20/32 (63%) 10/32 (31%) 22/32 (69%)
Sum
All FBN1 mutations 1,268 1,128/1,268 (89%) 140/1,268 (7%) 1,082/1,268 (85%) 188/1,268 (15%)
FBN1 mutations only in studies with 
suspected MFS
295 234/295 (90%) 25/295(10%) 238/295 (92%) 21/295 (8%)
Absence of FBN1 mutation 287 43/287 (15%) 244/287 (85%) 38/287 (13%) 249/287(87%)
Note: *including three patients with “potential MFS”.
Abbreviation: MFS, Marfan syndrome.
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the validity of the Ghent-1 or Ghent-2 criteria, we need an 
external diagnostic reference standard, which determines 
the “true” presence or absence of MFS, and would allow the 
sensitivity and specificity of nosologies to be calculated.92 
The defining criteria of a disease include etiology or clinical 
characteristics that allow for a clear delineation of the disease 
from both other diseases and the healthy population.56,59–61 
Similarly, none of the clinical characteristics of MFS mark 
a clear boundary to normality or to other diseases (Table 7), 
and none of the clinical signs of MFS is sufficient to prove or 
exclude MFS with both a sufficiently high positive likelihood 
ratio (.10) and a sufficiently low negative likelihood ratio 
(,0.1).32 Thus, there is no external diagnostic reference stan-
dard of MFS and, hence, there is no stringent way to assess 
diagnostic validity by measuring the sensitivity, specificity, 
or accuracy of the Ghent-1 and Ghent-2 nosology.93
In summary, the quality of diagnostic criteria of a specific 
nosology comprises objectivity, reliability, and validity, which 
have not been assessed in Ghent-1 or Ghent-2. Most nota-
bly, a nosology-based diagnosis of MFS lacks a diagnostic 
reference standard, and hence its sensitivity, specificity, or 
accuracy cannot be measured.
Perspectives from the clinic
The clinical perspective may be discussed in terms of the 
utility of the Ghent nosologies. In addition to objectivity, reli-
ability, and validity, the utility of diagnostic criteria has not 
been described uniformly. However, the idea that all concepts 
have in common is to assess the usefulness of the criteria for 
doctors, patients, and other persons or groups. Whereas valid-
ity is an invariant and dichotomous quality of a diagnostic 
category, utility is gradable and context-dependent.94 Based 
on the bio–social–psychological model of medicine, we will 
discuss the medical, social, and psychological dimension 
of the utility of diagnostic criteria using the example of the 
Ghent nosologies.95
Medical utility
The diagnosis of MFS should provide information that 
is congruent with the historical criteria of MFS; and that 
informs about the etiology, pathogenesis, diagnostic triggers, 
prognostic triggers, and potential complications (Table 2). All 
these pieces of information together guide therapeutic deci-
sions. Ideally, a single, easy, and quickly assessable criterion 
establishes the diagnosis of MFS which, at the same time, 
comprises all five types of information. As discussed earlier, 
this is not possible for MFS and, hence, diagnostic criteria 
compromise between feasibility and comprehensiveness. For 
instance, in contrast to Ghent-1, the Ghent-2 nosology does 
not list all diagnostic triggers. Indeed, this may not be neces-
sary, because tests for targeted screening for MFS are avai-
lable, and these may be used for the purpose of identifying 
patients in the general population (Table 3 and Figure 2).45–48 
Similarly, dural ectasia and mitral valve prolapse have a high 
prevalence in MFS and they may give rise to complications. 
However, there are many other manifestations of MFS that 
can also cause complications, and these prognostic triggers 
need monitoring once the diagnosis of MFS is established 
(Table 2). In conclusion, the Ghent-2 nosology focused on 
establishing the diagnosis of MFS easily and quickly. Accord-
ingly, Ghent-2 lists much fewer diagnostic criteria of MFS 
than does Ghent-1. At the same time, the diagnostic results 
are astonishingly congruent with the historical Ghent-2 
criteria.
Molecular analysis of the FBN1 gene can significantly 
reduce diagnostic uncertainty in suspected MFS. In Table 8, 
we analyze how FBN1 analysis improves the diagnosis of 
MFS according to Ghent-2 criteria. First, in the absence of 
a family history of MFS, all diagnostic scenarios (1–5) with 
the isolated or combined presence of aortic root dilatation, 
ectopia lentis, or systemic score points $7 allow one to estab-
lish the diagnosis of MFS when a causative FBN1 mutation 
is present. Even in patients with a MASS phenotype or with 
isolated ectopia lentis, the presence of an FBN1 mutation 
indicates the possibility that the phenotypes progress towards 
MFS during follow-up.32,96 Exclusion of an FBN1 mutation 
also yields a significant gain of diagnostic certainty in all five 
scenarios, where the presence of alternative diseases becomes 
very likely (scenarios 1–3) or where MFS can at least be 
excluded with a higher degree of certainty (scenarios 4 
and 5). In contrast, when the FBN1 gene is not analyzed, all 
diagnostic scenarios require extensive clinical and molecular 
analyses of many alternative syndromes (scenarios 1–3), or 
these scenarios remain diagnostically uncertain (scenarios 4 
and 5). Second, Ghent-2 allows for the diagnosis of MFS 
with the isolated presence of ectopia lentis, systemic score 
points $7, or aortic root dilatation in all individuals with 
the presence of a family history of MFS (scenarios 6–8). 
However, when the FBN1 mutation status is unknown in the 
entire family with MFS, then the diagnostic uncertainty about 
MFS may remain as illustrated in scenarios 1–5. In contrast, 
when an FBN1 mutation is known, the family diagnosis of 
MFS is possible in all diagnostic scenarios (6–8), even with-
out demonstrating the FBN1 mutation known in the family. 
However, testing for a specific nucleotide change in the FBN1 
gene can be done with minimum of effort, time, and money, 
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Table 8 Analysis of how FBN1 mutation status impacts the diagnosis of MFS according to current Ghent-2 diagnostic criteria
In the absence of FH FBN1 mutation present FBN1 unknown FBN1 mutation absent*
1. AoDD + eL MFS MFS after exclusion of SGS, LDS, veDS MFS after exclusion of SGS, LDS, veDS
2. AoDD + Syst $7 points MFS MFS after exclusion of SGS, LDS, veDS
3. AoDD MFS MFS or other GAS Other GAS
4. eL MFS† Uncertain No MFS
5. Syst $7 points‡ MFS Uncertain No MFS
In the presence of FH FBN1 present in family  
and in subject
FBN1 not assessed in family  
and in subject
FBN1 present in family, but not  
assessed in subject
6. eL MFS Uncertain MFS
7. Syst $7 points MFS Uncertain MFS
8. AoDD MFS Uncertain MFS if Z $2 above 20 years  
old, $2 below 20 years
Notes: *FBN1 gene is sequenced without showing a mutation; †with FBN1 mutation known to cause AoDD; ‡this diagnostic scenario is not addressed in the Ghent-2 nosology.
Abbreviations: MFS, Marfan syndrome; AoDD, aortic diameter at the sinuses of valsalva dilated $2 Z-scores or aortic root dissection; eL, ectopia lentis; SGS, Shprintzen–
Goldberg syndrome; LDS, Loeys–Dietz syndrome; veDS, vascular form of ehlers–Danlos syndrome; Syst, systemic score; GAS, genetic aortic syndrome; FH, family history 
of Marfan syndrome.
and these may be spent well, especially in subjects with an 
incomplete MFS phenotype (Table 8).
The definitive diagnosis of a specific genetic syndrome 
implies that there are different therapeutic approaches even to 
highly relevant manifestations, such as aortic root disease.75,93 
Hence, one should avoid relying on a solely clinical diagnosis 
of MFS.97,98 Whenever MFS remains uncertain or diagnostic 
triggers of other diseases are observed, phenotypes should 
be explained by the presence of alternative syndromes, such 
as Loeys–Dietz syndrome. Ghent-2 clearly encourages the 
exclusion of related syndromes through clinical evaluation, 
as well as through molecular mutation analysis, and hence 
it may improve the guidance of therapy.93
Social utility
Second, the social utility of the diagnostic criteria of MFS 
implies their acceptance by patients, patient organizations, 
the scientific community, doctors, hospital managers, and 
politicians. Thus, issues such as social labeling, identification 
with traditions, consistency with historical perceptions of 
MFS, scientific appropriateness, practicability, organizational 
needs, costs, social values, norms, and ethics come into play. 
Interestingly, both Ghent nosologies address most of these 
issues, however with a different emphasis. Ghent-2 mentions 
issues such as practicability and costs of diagnostics, consis-
tency with historical perceptions of MFS, and consequences 
of misdiagnosis, such as restriction of career choices or access 
to insurance benefits, financial burden through frequent medi-
cal care, unfounded marital or reproductive decisions, and 
psychosocial stigmatization. The costs of clinical diagnostics 
based on Ghent-1 nosology for an outpatient visit in Germany 
are €389 per year.99  Conversely, in Germany, the costs for 
conventional sequencing of the FBN1 gene are over €4,000, 
and these costs cannot be outweighed by a reduction in the 
clinical workup, as encouraged by Ghent-2.100,101
Psychological utility
Third, for patients, the psychological utility of the diagnostic 
criteria of MFS may imply a reduction of uncertainty, a miti-
gation of anxiety related to this uncertainty, and identification 
with a disease that has its own history; it also offers harborage 
for a community of patients, researchers, and doctors.102 It 
may be important that the consensus process of nosology revi-
sion is a real joint effort that involves the entire community 
of patient organizations, researchers, and expert clinicians. 
In the absence of an absolute truth, the German sociologist 
Niklas Luhmann suggested legitimation by procedure.103 For 
the quality and credibility of nosology criteria, rules of their 
development may be followed that are similar to those for 
official treatment guidelines, which may imply involvement 
of experts from all countries with Marfan centers, transpar-
ency of the process of expert selection, discussion, consensus, 
and disclosure of conflicts of interests.104
In summary, in contrast to the reliability of diagnostic 
criteria, which is invariant and dichotomous, the utility of 
diagnostic criteria is graded and context-dependent. Hence, 
the task of optimizing the utility of diagnostic criteria can 
be maximized only through negotiation, compromise, and 
consensus (Figure 1C).105,106 Since utility depends on context, 
prioritization of the various diagnostic rules remains an issue 
of strategic decision making.
Conclusion
Screening tests for MFS should be used to identify per-
sons with MFS. The Ghent-1 and Ghent-2 nosologies 
perform similarly, but Ghent-2 is much easier to use. Both 
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nosologies are formal rules that may have to be applied 
“with common sense and flexibility”, as Faivre et al80 have 
put it. We believe that one should not rely on a purely 
clinical diagnosis of MFS, but rather call for a molecular 
confirmation of MFS or alternative diagnoses. Similarly, 
regular aortic follow-up may be warranted in patients with 
a diagnosis of ectopia lentis syndrome, MASS phenotype, 
or MVPS.80 Finally, to maximize the utility of diagnostic 
rules, a fair and transparent process of their development 
is essential.
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